bioRxivPharmacology & Toxicology
Bepridil is Potent Against SARS-CoV-2 In Vitro
E. C. Vatansever, K. S. Yang, K. C. Kratch, A. Drelich, C.-C. Cho, D. M. Mellott, S. Xu, C.-T. K. Tseng, W. R. Liu
Abstract
Guided by a computational docking analysis, about 30 FDA/EMA-approved small molecule medicines were characterized on their inhibition of the SARS-CoV-2 main protease (MPro). Of these tested small molecule medicines, six displayed an IC50 value in inhibiting MPro below 100 M. Three medicines pimozide, ebastine, and bepridil are basic small molecules. Their uses in COVID-19 patients potentiate dual functions by both raising endosomal pH to slow SARS-CoV-2 entry into the human cell host and inhibiting MPro in infected cells. A live virus-based microneutralization assay showed that bepridil inhibited cytopathogenic effect induced by SARS-CoV-2 in Vero E6 cells completely at and dose-dependently below 5 M and in A549 cells completely at and dose-dependently below 6.25 M. Therefore, the current study urges serious considerations of using bepridil in COVID-19 clinical tests.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2
M. M. Ghahremanpour, J. Tirado-Rives, … W. L. Jorgensen·bioRxiv·Aug 28, 2020
- A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells
M. Mahoney, V. C. Damalanka, … J. W. Janetka·bioRxiv·May 6, 2021
- Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
C. Ma, M. D. Sacco, … J. Wang·Cell ResearchPeer-reviewed·Jun 15, 2020
- Novel inhibitors against COVID-19 main protease suppressed viral infection
V. Ramachandran, Y. Liu, … R. Chang·bioRxiv·Nov 5, 2022
- Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors
- Erythromycin, Retapamulin, Pyridoxine, Folic acid, and Ivermectin dose-dependently inhibit cytopathic effect, Papain-like Protease, and MPRO of SARS-CoV-2
S. O. Bello, M. U. Imam, … I. Okoye·bioRxiv·Dec 28, 2022